2023-06-06 06:24:37 ET
- Intellipharmaceutics International press release ( OTC:IPCIF ): FY GAAP EPS of -$0.09.
- Revenue of $0.06M.
- For First Quarter 2023: The Company recorded GAAP EPS of -$0.01/common share.
- The company recorded revenues of $0.33M for the three months ended February 28, 2023 versus $0.08 for the three months ended February 28, 2022.
- As of November 30, 2022, cash balance was $0.08M and as of February 28, 2023, cash balance was $0.07M.
- "We currently expect to meet our short-term cash requirements from potential revenues for approved generic products or other collaborations, other available financing and by cost savings resulting from reduced R&D activities and staffing levels, as well as quarterly profit share from Par."
For further details see:
Intellipharmaceutics International reports FY 2022 and Q1 2023 results